Cubist Pharmaceuticals plans to acquire antibiotics-makers Optimer Pharmaceuticals for $801 million and Trius Therapeutics for $818 million contingent on certain milestones in a bid to increase its product pipeline. The deal grants Cubist access to Optimer's recently approved drug Dificid for Clostridium difficile-associated diarrhea and Trius' late-stage antibiotic tedizolid phosphate.

Related Summaries